Roy and Bob Z ----- RE Ligand's Potential Markets
I gave this link before, so pardon the repetition
- but the information Roy asked about is presented compactly.
Once inside this link - Ligand Corporate Profile (from Research Magazine)
researchmag.com;
CLICK Potential Markets.
----------------------
They mention only 2 drugs, but list indications and numbers
(I cut in the following, because they were working on their site as I was typing -- and who knows if the link is still there . . .)
Potential Markets
TargretinTM (LGD1069):
NEW PATIENTS PER YEAR (U.S.)
Actinic keratoses: 1.5 million
Diabetes (Type II): 15 million (total patients)
Head and neck cancer: 39,750
Kaposi's sarcoma: 22,200
Lung cancer: 169,900
Ovarian cancer: 26,600
Prostate cancer: 244,000
Skin lymphoma: 6,000
------------------
PanretinTM* (ALRT1057):
NEW PATIENTS PER YEAR (U.S.)
APL: 2,500
Breast cancer: 182,000
Kaposi's sarcoma: 22,200
Ovarian cancer: 26,600
Prostate cancer: 244,000
Severe psoraisis: 157,000
---------------
To All:
Do you have any corrections/comments about Research Mag's list for these two drugs? |
